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INTRODUCTION
Cancer is a major cause of death, for which early diagnosis and 
treatment remain the best strategy to improve prognosis and quality 
of life [1,2]. Improving understanding of the molecular mechanisms 
that underlie the malignant transformation of cancer cells may lead 
to the development of new therapeutic strategies to fight cancer [3]. 
Worldwide, 1.2 million new cases of CRC occur annually, accounting 
for about 10% of all cancers, with a mortality rate of approximately 
600,000 [4]. The latest WHO findings cited in GLOBOCAN, is 
estimated that about 10,96,000 new cases of colorectal cancer will 
be diagnosed in 2018, while the expected number was 7,04,000. In 
total, these include 1.8 million new CRC cases [5].
After chemotherapy, more than 50% of patients with CRC relapse, 
typically with metastasis and 5-year survival of only 10% [6]. In recent 
years, the pathways for controlling apoptosis, cell proliferation, 
tumour progression and differentiation, as well as the pathogenic 
mechanisms of associated processes, have been evaluated to 
identify the prognostic factors in CRC [7]. Though they are less 
well understood, epigenetic mechanisms may be as significant as 
mutations [8]. To date, however, the only reliable prognostic markers 
in CRC are mutations in BRAF and the RAS family [9,10]. Therefore; 
clinicians need a better understanding of the biology of CRC and to 
identify new therapeutic goals [11].
Despite a growing knowledge base, data on the role of EZH2 in 
CRC are scanty and inconclusive [6] EZH2 is known to be a catalytic 
unit of the epigenetic regulator of Polycomb Repressive Complex 2 
(PRC2) on chromosome 7q35 [12], which affects SUZ12 polycomb 
repressive complex 2 subunits and the development of embryonic 
ectoderm necessary for trimethylating histone 3 lysine residue 27 
[13,14]. Recent studies have shown that over-expression or mutation 
of EZH2 occurs in several malignancies [15,16], where it is associated 
with cell proliferation, invasion, apoptosis, angiogenesis, metastasis, 
stem cell maintenance, drug resistance, and disease progression; 
thus, EZH2 is an attractive anti-cancer target [17-20]. Although it 
has been consistently reported that EZH2 is expressed in CRC, it is 
unclear whether this expression is positively [21], negatively [22,23], 
or not associated with patient survival [24]. Also, only one study has 
considered the role of EZH2 in the growth of CRC cells [24].
This study aimed to study the clinicopathologic significance of EZH2 
expression in CRC, the association between EZH2 expression and 
important clinical variables, and the DFS and OS.
MATERIALS AND METHODS
This was a retrospective study of primary surgical procedures for 
CRC performed at Tabriz University of Medical Sciences, Tabriz, 
Iran, from April 2009 to June 2019. In this study, all participants gave 
informed consent for the participation in the study and using their 
Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples. The ethics 
committee of Tabriz University of Medical Sciences approved the study 
protocol (permit no 5/d/86136). All patients suspected of colorectal 
cancer were undergoing colonoscopy. After histological confirmation 
of colorectal cancer, they were undergoing surgical procedures. All 
patients in Stage II and III with colorectal cancer treated with FOLFOX 4 
or XELOX protocol, as the routine of oncology ward. Also, patients with 
rectal cancer underwent radiotherapy. Patients with Stage IV diseases 
checked for KRAS mutations, and in cases with wild type K-RAS, they 
received anti-EGFR target therapies and chemotherapy too.
Follow-up of the Patients
In non-metastatic colorectal cancer, patients followed every three 
months for three years, every six months for five years, and then 
annually. Also, colonoscopy performed for them every three years. 
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ABSTRACT
Introduction: It has been reported that Enhancer of Zeste 
Homolog 2 (EZH2) enhancer is expressed in Colorectal Cancer 
(CRC), but there are only limited findings of its overexpression 
with prognosis in CRC.
Aim: To investigate the association between EZH2 expression 
and clinicopathologic variables and outcome in CRC.
Materials and Methods: This retrospective study retrieved 
the archived histological samples for immunohistochemistry 
evaluation of EZH2 and PCR analysis of KRAS from patients with 
CRC who were followed-up between April 2009 and February 
2019. Kaplan-Meier methods were used for Overall Survival 
(OS) and Disease-Free Survival (DFS). Cox proportional hazard 
model and time dependent Cox model were used to evaluating 
association of clinicopathologic factors with OS and DFS.
Results: Hundred patients with CRC were included with mean 
age and range 57.39±13.52 years and 21-83 years. There were 
no significant association between OS (log-rank p-value=0.50) 
and DFS (log-rank p-value=0.74) with EZH2 expression. Third 
quartile of OS was 30.7 days and for DFS was 107.83 days.
According to the result of multivariate cox regression after 
adjusting for confounding variables, there was no significant 
association between EZH2 and OS (HR =1.53, 95% CI=0.63-3.72, 
p=0.35). Also, a borderline association was observed between 
EZH2 and DFS (HR=11.08, 95% CI=1.02-119.72, p=0.05). There 
were no significant associations between the DFS, OS and other 
clinicopathologic parameters except for the stage, respectively 
(HR=3.51, 95% CI=1.71-7.20, p=0.001) (HR=3.55, 95% CI=1.71-
7.35, p=0.001).
Conclusion: The expression of EZH2 in patients with CRC was 
not associated with clinical features, and does not appear to 
be associated with OS or DFS. EZH2 is an attractive target in 
cancer and much more research is clearly warranted.
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RESULTS
Patients and specimens: Enrolled 100 colorectal cancer patients 
with mean age of 57.60±13.68 years (range of 21-83 years).
association of eZh2 expression with clinicopathological 
aspects: The high EZH2 was expression in 86 (86%) of the patients 
and Low expression in 14 (14%). There was no association between 
EZH2 expression and clinicopathologic parameters Also, there was 
no significant association observed between EZH2 and KRAS, 
(p=0.92) [Table/Fig-2].
In metastatic patients, treatment was continued until the disease 
progresses, or if the side-effects of the drug were seen. The survival 
analysis in association of different treatment methods was out of aims of 
the present study. The OS and DFS were the outcomes of interest. OS 
was defined as the time from history of surgery to death from CRC, and 
DFS was defined as the time to recurrence or the last follow-up date.
IHC Analysis
All cases were retrieved the archived (FFPE) tissue samples (stained 
with haematoxylin and eosin) and tested them to confirm the 
pathological diagnosis and grade based on the 2017 World Health 
Organisation classification of CRC. Tumour size, nodal involvement, 
metastasis was estimated by (TNM) staging according to the 
seventh edition of the American Joint Committee on Cancer [25].
Sections for IHC analysis were deparaffinised through graded 
alcohols and xylene, placed in an EDTA buffer solution (pH 9.0) and 
then heated to 100°C in a microwave oven at 900 W for 2-5 minutes 
and 180 W for 5 minutes until boiling. Then, the slides were left in the 
solution to cool down at room temperature for ~15 minutes and were 
rinsed in tris-buffered saline (pH=7.6) for 5 minutes. Endogenous 
peroxidase with 3% hydrogen peroxidase in methanol was added for 
10 minutes to block non-specific binding, and then the slides were 
incubated with the primary antibodies overnight in 4°C. The following 
primary antibodies were used: EZH2 (AV38470 100 UG; QC: 10904; 
Sigma) 1.15 diluted phosphate-buffered saline solution. After the 
slides were incubated in secondary antibody for 30 minutes again 
incubated in Tris buffer for 5 minutes and incubated with chromogen 
for 5 minutes. Finally, the slides were washed in Tris buffer saline, 
prior to sealing a coverslip, counterstained with haematoxylin, and 
dehydrated with alcohols (96% and 100%) and xylene [2].
EZH2 immunostaining score was incorporated both staining intensity 
(0=Negative, 1=Weak, 2=Intermediate, 3=Intensive) and percentage of 
positive cells (0=0%, 1=>0 -<1%, 2=1-10%, 3=11-33%, 4=34-66%, 
5=>67%). The total score of the intensity and the proportion were 
expressed as the final score. Patients with (range 0-4) expression were 
combined as the lower expression group, and patients with (range 5) 
expression were combined as the higher expression group for analyses 
[Table/Fig-1a-c] [26].
Paraffin blocks of patients with colorectal cancer were used to 
evaluate the mutation of KRAS. It was cut to 5 μm for PCR by the 
Idylla Biocartis NV system (2800 Mechelen, Belgium, BCT006631), in 
the reference molecular lab, for codons 12, 13, 59, 61, 117, and 146.
[Table/Fig-1]: Immunohistochemical analysis of EZH2 in colorectal cancer (100X).
(a) Haemotoxylin and eosin stain; (b) high expression; and (c) low expression.
STATISTICAL ANALYSIS
The association between EZH2 level (low and high level of EZH2) 
and clinicopathologic parameters was evaluated by Chi-square 
test. The Kaplan-Meier method was used to evaluate survival 
rates and log rank test was used to compare survival of patients 
with low and high level of EZH2. The uni- and multi-variate Cox 
proportional hazard regression analysis was performed to evaluated 
association of EZH2 with OS and PFS, unadjusted and adjusted for 
confounding variables (Age, Sex, Grade, Stage, EZH2 expression), 
respectively. The proportional hazards assumption for Cox regression 
was evaluated based on Schönfeld residuals. To determine the 
predictive power of EZH2 at the Survival Rate, the Harrell’s C-index 
was calculated. The p-value <0.05 was considered significant. All 
statistical analyses were performed in STATA, version 14.
Variables total eZh2 low (%) high (%) p-value
Age
<50 32 6 (18.8) 26 (81.3)
0.36
≥50 68 8 (11.8) 60 (88.2)
Sex
Female 41 6 (14.6) 35 (85.4)
0.80
Male 59 8 (13.6) 51 (86.4)
Site
Ascending 22 3 (13.6) 19 (86.4)
0.70Transverse 4 0 (0) 4 (100)
Descending and rectum 74 11 (14.9) 63 (85.1)
Grade
I 63 7 (11.1) 56 (88.9)
0.41II 34 6 (17.6) 28 (82.4)
III 3 1 (33.3) 2 (66.7)
T
I 1 0 (0) 1 (100)
0.90
II 22 4 (18.2) 18 (81.8)
III 44 6 (13.6) 38 (86.4)
IV 33 4 (12.1) 29 (87.9)
N
Positive 51 8 (15.7) 43 (84.3)
0.62
Negative 49 6 (12.2) 43 (87.8)
M
Positive 3 3 (13.6) 13 (86.4)
0.95
Negative 11 11 (14.1) 67 (85.9)
Stage
I, II 41 6 (14.6) 35 (85.4)
0.87
III, IV 59 8 (13.6) 51 (86.4)
KRAS 
Wild 7 1 (14.3) 6 (85.7)
0.92Mutant 5 1 (20) 4 (80)
Unknown 87 12 (13.8) 75 (86.2)
DFS
Without relapse 54 7 (13) 47 (87)
0.74
Relapse 46 7 (15.2) 39 (84.8)
OS
Alive 56 8 (14.3) 48 (85.7)
0.92
Death 44 6 (13.6) 38 (86.4)
[Table/Fig-2]: Clinicopathologic characteristics of patients with colon cancer according 
to the EZH2 level.
DFS: Disease free survival; OS: Overall survival; EZH2: Enhancer of zeste homolog 2
Survival analysis by expression of eZh2: The patients who died 
by the end of the follow-up were 44%. The third quartile of the 
overall survival distribution (the latest time that at least 75 % of the 
patients were still alive) was 30.7 days and second quartile (median) 
of survival time was 73.367 days. Because of low rate of event, the 
survival curve does not drop to 0.25 or below. So, the first quartile 
could not be computed. The mean survival time was 80.55 days. 
There were no significant association between OS and high or low 
EZH2 expression (log-rank p=0.50; [Table/Fig-3a].
The third quartile of the survival time for DFS (the latest time that at 
least 75 % of the patients were still alive without any recurrence) was 
25.37 days and median time to relapse was 107.83 days. Because 
of low rate of event, the survival curve does not drop to 0.25 or 
below. So, the first quartile could not be computed. The mean 
survival time was 77.81 days. There were no significant association 
between DFS and high or low EZH2 expression (log-rank p=0.74; 
[Table/Fig-3b].
association between patient outcome and eZh2 ihC 
expression: The proportion hazard assumption was satisfied for OS 
(p-value=0.19). The Univariate proportional hazard Cox regression 
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trimethylating histone 3 lysine residue 27 [13,14]. Recent studies 
have shown that over-expression or mutation of EZH2 occurs in 
several malignancies [15,16]. EZH2 plays an important role in the 
proliferation, invasion, apoptosis, angiogenesis, metastasis, drug 
resistance, and progression of cancer [2,18,19]. This Oncogene is 
important to cancer growth through epigenetic silencing of tumour 
suppressor gene expression [30]. It is known to be over-expressed 
in prostate cancer [31], lung cancer [32], breast cancer [33], liver 
cancer [34], and CRC [6] and has a demonstrable association 
with invasive clinical manifestations [7]. Although incompletely 
understood, abnormalities of EZH2 and its underlying mechanisms 
appear to be involved in the pathogenesis of CRC, with a significantly 
increased expression reported [35].
In this study, the present authors evaluated EZH2 expression in 
100 samples of CRC, identifying that EZH2 expression was high in 
86 patients and low in only 14 patients. There was no association 
between EZH2 expression and clinicopathologic parameters. 
Boostani F et al., reported that high EZH2 expression was 
associated with clinicopathological features in breast cancer [2]. 
The present authors could not find any association between any 
clinicopathological factors and EZH2 expression in CRC. Jiang T et 
al., reported that high EZH2 expression could be a prognostic factor 
for both OS and DFS in lung cancer [14]. The present authors also 
evaluated the association of EZH2 expression with OS and DFS in 
CRC. EZH2 over-expression was not associated with OS (HR=1.53, 
95% CI=0.63-3.72, p=0.35). In association of EZH2 expression with 
DFS (HR=0.93, 95% CI=0.90-0.10, p=0.05), but considering to the 
wide confidence interval, this risk ratio needs further investigation.
As has been shown, KRAS is one of the factors indicating prognosis 
in patients with CRC. Because only 12 tests were available in 
metastatic patients, survival analysis did not seem statistically 
significant, so survival analysis was not performed.
In a meta-analysis of studies in Asia, Chen S et al., noticed that EZH2 
over-expression was significantly associated with stage and lymph 
node metastasis, but not with T status [17]. They concluded that it 
was not possible to confirm the presence of a definite relationship 
between EZH2 expression and specific carcinoma types because 
there were too few studies available for anyone type of cancer. In the 
present study authors didn’t find significant associations between 
the DFS, OS and clinicopathologic parameters except for the stage, 
respectively (HR=3.51, 95% CI=1.71-7.20, p=0.001) (HR=3.55, 
95% CI=1.71-7.35, p=0.001). Given that Iran is in Asia, conducting 
further studies with more samples in this population could improve 
our knowledge of the effect of EZH2 on CRC.
Limitation(s)
There are some limitations that need to be considered with this 
research. There was a small sample size which could lead to 
possibility of superiority bias. The study used a shorter follow-up 
period to analyse survival (which will have made it difficult to assess 
the effect of EZH2 on disease progression and mortality). The data 
interpretation was hindered by the lack of an established gold 
standard for expressing the EZH2 score, which was performed at 
home in this study. Previous researchers have used different EZH2 
ranking methods, so it is possible that this difference in approach 
accounted for the lack of comparability between data sets. KRAS 
test were not available for most of the metastatic patients. Despite 
these limitations, the present study benefits from having evaluated a 
series of CRCs from a single institute.
CONCLUSION(S)
In patients with CRC, it was found that EZH2 expression was not 
associated with clinical features and that it does not appear to be 
associated with OS or DFS. EZH2 is an attractive target for cancer 
treatment, but much more research is clearly warranted. Specifically, 
there is a need to resolve issues with the scoring method and the 
[Table/Fig-3]: Kaplan-Meier curves showing association of EZH2 expression in 
patients with colorectal cancer. (a) Overall survival (p=0.50); and (b) Disease-Free 
Survival (p=0.74).
analysis showed that OS was no association with EZH2 expression 
(HR=1.34, 95% CI=0.57-3.19, p=0.50). Proportional hazard Cox-
regression analysis after adjustment for other clinicopathologic 
parameters showed that OS was not significantly associated with 
EZH2 (HR=1.53, 95% CI=0.63-3.72, p=0.35). Harrell’s-C index for 
OS was 0.52.
The proportion hazard assumption was not satisfied with DFS 
(p-value=0.009). This indicates that the risk ratio of outcome in the 
two EZH2 groups varied significantly over time. Due to the lack of 
proportionality assumption, the Cox model with time dependent 
covariate was processed to the data instead of the conventional Cox 
model. The time-dependent variable was defined as the interaction 
between time and the EZH2 variable. After entering the time-
dependent variable into the model, the proportionality assumption 
was established (p-value=0.71). The result of the time dependent 
Cox model did not show significant effect for the EZH2 variable 
(HR=7.88 95% CI= .79-78.13, p=.07). In multivariate Cox model for 
DFS with time dependent variable and adjustment for confounders, 
the risk level for high EZH2 group was 11.08 times higher than the 
low EZH2 group (HR=11.08, 95% CI=1.02-119.72, p=0.05).
There were no significant associations between the DFS, OS and 
other clinicopathologic parameters except for the stage, respectively 
(HR=3.51, 95% CI=1.71-7.20, p=0.001) (HR=3.29, 95% CI=1.59-
6.79, p=0.001) [Table/Fig-4].
Variables DfS hr (95% Ci) p-value* OShr (95% Ci) p-value**
Age
<50 Ref Ref
≥50 1.21 (0.60-2.49) 0.60 1.42 (0.70-2.93) 0.33
Sex
Female Ref Ref
Male 0.70 (0.40-1.30) 0.24 0.82 (0.44-1.50) 0.51
Grade
I Ref Ref
II 0.98 (0.51-1.87) 0.92 1.17 (0.61-2.25) 0.62
III 3.85 (0.73-20.12) 0.11 3.24 (0.64-16.30) 0.15
Stage
I, II Ref Ref
III, IV 3.55 (1.71-7.35) 0.001 3.30 (1.60-6.80) 0.001
EZH2
Low Ref Ref
High 11.08 (1.02-119.72) 0.05 1.53 (0.63-3.72) 0.34
[Table/Fig-4]: Hazard ratios of EZH2 for DFS and OS adjusted for Clinicopathologic 
characteristics of patients with colon cancer (Multivariate Cox Proportional-Hazards 
Regression model).
Lower: Lower bound for 95%; CI: Upper, upper bound for 95%; CI: Adjusted variables: Age, Sex, 
Grade, Stage
*p-value from time dependent cox regression; **p-value from proportion hazard cox regression
EZH2: Enhancer of zeste homolog 2; DFS: Disease free survival; OS: Overall survival
DISCUSSION
CRC was the third most common cancer in the world in 2013 
according to Global Burden of Cancer report [27]. Moreover, the 
worldwide incidence increased from 1.2 million to 1.7 million cases 
between 2005 and 2015, representing an overall increase of 36.5% 
[28,29]. When adjusting for population ageing and growth, even 
between comparable populations, cases of CRC increased by 5% 
in Iran over that period, such that it is now the fifth most common 
cancer [27]. EZH2 is epigenetic regulator of Polycomb Repressive 
Complex 2 (PRC2) on chromosome 7q35 [12], which necessary for 
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